UES, upper esophageal sphincter

  • 文章类型: Journal Article
    目的:食管功能检测是评价难治性GERD和食管动力紊乱的重要组成部分。这篇综述总结了目前可用于食管功能测试的技术,包括功能性管腔成像探头(FLIP),高分辨率食管测压(HRM),和多通道管腔内阻抗(MII)和pH监测。
    方法:我们进行了MEDLINE,PubMed,和MAUDE数据库文献检索,使用以下关键词识别到2021年3月的相关临床研究:食管测压,HRM,食管阻抗,FLIP,MII,和食道pH检测。技术数据来自传统和网络出版物,专有出版物,以及与相关供应商的非正式沟通。报告起草完毕,reviewed,由美国胃肠内窥镜技术委员会编辑,并由美国胃肠内窥镜学会理事会批准。
    结果:FLIP是一种高分辨率阻抗平面测量系统,用于食道中的压力和尺寸测量,幽门,还有肛门括约肌.FLIP为食管运动障碍的人力资源管理提供补充信息,尤其是贲门失弛缓症.芝加哥分类,基于人力资源管理数据,是一种广泛采用的用于诊断食管运动障碍的算法方案。MII检测腔内推注运动,结合pH测量或测压,提供有关难治性GERD患者的酸性和非酸性胃食管反流和推注转运的信息,以及抗反流手术的术前评估。
    结论:食管功能测试技术(FLIP,HRM,和MII-pH)在评估食管运动障碍和难治性GERD中具有诊断和预后价值。较新的技术和分类系统使人们对这些疾病有了更多的了解。
    OBJECTIVE: Esophageal function testing is an integral component of the evaluation of refractory GERD and esophageal motility disorders. This review summarizes the current technologies available for esophageal function testing, including the functional luminal imaging probe (FLIP), high-resolution esophageal manometry (HRM), and multichannel intraluminal impedance (MII) and pH monitoring.
    METHODS: We performed a MEDLINE, PubMed, and MAUDE database literature search to identify pertinent clinical studies through March 2021 using the following key words: esophageal manometry, HRM, esophageal impedance, FLIP, MII, and esophageal pH testing. Technical data were gathered from traditional and web-based publications, proprietary publications, and informal communications with pertinent vendors. The report was drafted, reviewed, and edited by the American Society for Gastrointestinal Endoscopy Technology Committee and approved by the Governing Board of the American Society for Gastrointestinal Endoscopy.
    RESULTS: FLIP is a high-resolution impedance planimetry system used for pressure and dimension measurement in the esophagus, pylorus, and anal sphincter. FLIP provides complementary information to HRM for esophageal motility disorders, especially achalasia. The Chicago classification, based on HRM data, is a widely adopted algorithmic scheme used to diagnose esophageal motility disorders. MII detects intraluminal bolus movement and, combined with pH measurement or manometry, provides information on acid and non-acid gastroesophageal reflux and bolus transit in patients with refractory GERD and for preoperative evaluation for anti-reflux procedures.
    CONCLUSIONS: Esophageal function testing techniques (FLIP, HRM, and MII-pH) have diagnostic and prognostic value in the evaluation of esophageal motility disorders and refractory GERD. Newer technologies and classification systems have enabled an increased understanding of these diseases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    吞咽困难是常见的,头颈部肿瘤治疗后的严重和剂量限制性毒性(HNC)。本研究旨在研究治疗性(化学)放射治疗(RT)后HNC患者的正常吞咽结构与患者报告的放射剂量之间的关系以及临床测量的吞咽功能,重点是后期效果。
    2007-2015年接受RT±化疗治疗的HNC患者(n=90)通过电话访谈和视频透视(VFS)评估治疗后吞咽困难。研究特定的症状评分用于确定患者报告的吞咽困难。应用穿透抽吸量表(PAS)通过VFS确定吞咽功能(PAS≥4/≥6=中度/重度吞咽困难)。在患者的原始计划CT扫描和检索的相关剂量-体积直方图(DVH)上分别描绘了正常吞咽中涉及的13个解剖结构。通过单变量和多变量逻辑回归分析(UVA/MVA)研究了结构剂量与晚期毒性之间的关系,并考虑了相关临床因素的影响。
    中位评估时间为RT后7个月(范围:5-34个月)。对侧腮腺和声门上喉的平均剂量以及对侧前腹肌的最大剂量预测了患者报告的吞咽困难(AUC=0.64-0.67)。咽缩肌的平均剂量,喉部,声门上喉和会厌,以及对侧颌下腺的最大剂量通过VFS预测了中度和重度吞咽困难(AUC=0.71-0.80)。
    该队列中的患者在治疗前被连续识别,并在治疗后的特定时间点进行结构接近和评估吞咽困难。除了确定的吞咽困难危险器官(OAR),我们的数据表明,会厌和颌下腺剂量对RT后吞咽功能很重要.保持DVH阈值低于V60=60%和V60=17%,分别,可能会增加机会,以减少严重的晚期吞咽困难的发生。结果需要在未来的研究中进行外部验证。
    UNASSIGNED: Dysphagia is a common, severe and dose-limiting toxicity after oncological treatment of head and neck cancer (HNC). This study aims to investigate relationships between radiation doses to structures involved in normal swallowing and patient-reported as well as clinically measured swallowing function in HNC patients after curative (chemo-) radiation therapy (RT) with focus on late effects.
    UNASSIGNED: Patients (n = 90) with HNC curatively treated with RT ± chemotherapy in 2007-2015 were assessed for dysphagia post-treatment by telephone interview and videofluoroscopy (VFS). A study-specific symptom score was used to determine patient-reported dysphagia. The Penetration-Aspiration Scale (PAS) was applied to determine swallowing function by VFS (PAS ≥ 4/ ≥ 6 = moderate/severe dysphagia). Thirteen anatomical structures involved in normal swallowing were individually delineated on the patients\' original planning CT scans and associated dose-volume histograms (DVHs) retrieved. Relationships between structure doses and late toxicity were investigated through univariable and multivariable logistic regression analysis (UVA/MVA) accounting for effects by relevant clinical factors.
    UNASSIGNED: Median assessment time was 7 months post-RT (range: 5-34 months). Mean dose to the contralateral parotid gland and supraglottic larynx as well as maximum dose to the contralateral anterior digastric muscle predicted patient-reported dysphagia (AUC = 0.64-0.67). Mean dose to the pharyngeal constrictor muscle, the larynx, the supraglottic larynx and the epiglottis, as well as maximum dose to the contralateral submandibular gland predicted moderate and severe dysphagia by VFS (AUC = 0.71-0.80).
    UNASSIGNED: The patients in this cohort were consecutively identified pre-treatment, and were structurally approached and assessed for dysphagia after treatment at a specific time point. In addition to established dysphagia organs-at-risk (OARs), our data suggest that epiglottic and submandibular gland doses are important for swallowing function post-RT. Keeping DVH thresholds below V60 = 60% and V60 = 17%, respectively, may increase chances to reduce occurrence of severe late dysphagia. The results need to be externally validated in future studies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号